Is CBUS or QNCX more profitable?

Quince Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Quince Therapeutics' return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% Quince Therapeutics N/A N/A -133.84%

Does the media favor CBUS or QNCX?

In the previous week, Cibus had 5 more articles in the media than Quince Therapeutics. MarketBeat recorded 10 mentions for Cibus and 5 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.07 beat Cibus' score of -0.28 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cibus 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, QNCX or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is QNCX or PMN more profitable?

Quince Therapeutics' return on equity of 0.00% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Promis Neurosciences N/A -143.09% -109.15%

Does the media refer more to QNCX or PMN?

In the previous week, Promis Neurosciences had 6 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for Promis Neurosciences and 5 mentions for Quince Therapeutics. Promis Neurosciences' average media sentiment score of 0.44 beat Quince Therapeutics' score of 0.07 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is QNCX or ADCT more profitable?

Quince Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% ADC Therapeutics -121.77% N/A -32.74%

Does the media prefer QNCX or ADCT?

In the previous week, Quince Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.54 beat Quince Therapeutics' score of 0.07 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QNCX or GNLX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Genelux N/A -205.85% -138.79%

Does the media refer more to QNCX or GNLX?

In the previous week, Genelux had 17 more articles in the media than Quince Therapeutics. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Quince Therapeutics. Genelux's average media sentiment score of 0.45 beat Quince Therapeutics' score of 0.07 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is QNCX or ANIX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Anixa Biosciences N/A -71.12% -62.88%

Does the media refer more to QNCX or ANIX?

In the previous week, Quince Therapeutics had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for Anixa Biosciences. Quince Therapeutics' average media sentiment score of 0.07 beat Anixa Biosciences' score of -0.83 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Quince Therapeutics (QNCX) Competitors

$33.93 +1.82 (+5.67%)

As of 08/21/2026 04:00 PM Eastern

Compare

QNCX vs. CBUS, PMN, ADCT, GNLX, and ANIX

Should you buy Quince Therapeutics stock or one of its competitors? Quince Therapeutics's main competitors and comparable companies include Cibus (CBUS), Promis Neurosciences (PMN), ADC Therapeutics (ADCT), Genelux (GNLX), and Anixa Biosciences (ANIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Quince Therapeutics compare to Cibus?

Cibus (NASDAQ:CBUS) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Cibus currently has a consensus price target of $9.00, suggesting a potential upside of 429.41%. Quince Therapeutics has a consensus price target of $260.00, suggesting a potential upside of 666.28%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.33

33.8% of Cibus shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 29.9% of Cibus shares are owned by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Quince Therapeutics has lower revenue, but higher earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	35.70	-$127.08M	-$1.65	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Quince Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Quince Therapeutics' return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Quince Therapeutics	N/A	N/A	-133.84%

In the previous week, Cibus had 5 more articles in the media than Quince Therapeutics. MarketBeat recorded 10 mentions for Cibus and 5 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.07 beat Cibus' score of -0.28 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cibus	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cibus has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Summary

Quince Therapeutics beats Cibus on 9 of the 16 factors compared between the two stocks.

How does Quince Therapeutics compare to Promis Neurosciences?

Quince Therapeutics (NASDAQ:QNCX) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Promis Neurosciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

Quince Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market.

Quince Therapeutics currently has a consensus target price of $260.00, indicating a potential upside of 666.28%. Promis Neurosciences has a consensus target price of $34.00, indicating a potential upside of 134.32%. Given Quince Therapeutics' higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.33
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Promis Neurosciences had 6 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for Promis Neurosciences and 5 mentions for Quince Therapeutics. Promis Neurosciences' average media sentiment score of 0.44 beat Quince Therapeutics' score of 0.07 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quince Therapeutics' return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Promis Neurosciences	N/A	-143.09%	-109.15%

Summary

Promis Neurosciences beats Quince Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Quince Therapeutics compare to ADC Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Quince Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
ADC Therapeutics	$81.36M	1.57	-$142.62M	-$0.66	N/A

In the previous week, Quince Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.54 beat Quince Therapeutics' score of 0.07 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quince Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
ADC Therapeutics	-121.77%	N/A	-32.74%

Quince Therapeutics presently has a consensus price target of $260.00, suggesting a potential upside of 666.28%. ADC Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 401.30%. Given Quince Therapeutics' higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.33
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Quince Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

Summary

Quince Therapeutics beats ADC Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Quince Therapeutics compare to Genelux?

Quince Therapeutics (NASDAQ:QNCX) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Quince Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Genelux	N/A	-205.85%	-138.79%

Quince Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Genelux has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Quince Therapeutics presently has a consensus price target of $260.00, indicating a potential upside of 666.28%. Genelux has a consensus price target of $18.00, indicating a potential upside of 561.76%. Given Quince Therapeutics' higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.33
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has higher revenue and earnings than Quince Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Genelux	$10K	12,305.28	-$32.15M	-$0.86	N/A

In the previous week, Genelux had 17 more articles in the media than Quince Therapeutics. MarketBeat recorded 22 mentions for Genelux and 5 mentions for Quince Therapeutics. Genelux's average media sentiment score of 0.45 beat Quince Therapeutics' score of 0.07 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genelux beats Quince Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to Anixa Biosciences?

Quince Therapeutics (NASDAQ:QNCX) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Anixa Biosciences has higher revenue and earnings than Quince Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Anixa Biosciences	$210K	601.02	-$10.93M	-$0.31	N/A

Quince Therapeutics presently has a consensus target price of $260.00, indicating a potential upside of 666.28%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 129.11%. Given Quince Therapeutics' higher probable upside, equities research analysts plainly believe Quince Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.33
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Quince Therapeutics' return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Anixa Biosciences	N/A	-71.12%	-62.88%

Quince Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

In the previous week, Quince Therapeutics had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for Anixa Biosciences. Quince Therapeutics' average media sentiment score of 0.07 beat Anixa Biosciences' score of -0.83 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Quince Therapeutics beats Anixa Biosciences on 9 of the 15 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.51M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-0.22	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	-0.98	16.80	13.05	6.20
Net Income	-$83.98M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-0.32%	3.29%	2.09%	0.08%
1 Month Performance	85.61%	8.23%	6.64%	3.88%
1 Year Performance	-89.59%	55.05%	25.02%	16.98%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	2.6686 of 5 stars	$33.93 +5.7%	$260.00 +666.3%	-89.6%	$34.51M	N/A	N/A	60	News Coverage Earnings Report Analyst Forecast Gap Up
CBUS Cibus	1.4112 of 5 stars	$1.67 -5.6%	$9.00 +438.9%	+24.1%	$135.11M	$4.35M	N/A	48	Analyst Revision
PMN Promis Neurosciences	3.4666 of 5 stars	$14.66 -1.3%	$31.50 +114.9%	+8.3%	$133.26M	N/A	N/A	5	Analyst Forecast Analyst Revision
ADCT ADC Therapeutics	3.5355 of 5 stars	$1.09 +7.9%	$5.00 +358.7%	-68.5%	$128.46M	$81.36M	N/A	310	High Trading Volume
GNLX Genelux	2.2188 of 5 stars	$2.70 -1.5%	$18.00 +566.7%	-28.0%	$122.86M	$10K	N/A	10	News Coverage Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. CBUS, PMN, ADCT, GNLX, and ANIX

How does Quince Therapeutics compare to Cibus?

Summary

How does Quince Therapeutics compare to Promis Neurosciences?

Summary

How does Quince Therapeutics compare to ADC Therapeutics?

Summary

How does Quince Therapeutics compare to Genelux?

Summary

How does Quince Therapeutics compare to Anixa Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. CBUS, PMN, ADCT, GNLX, and ANIX

How does Quince Therapeutics compare to Cibus?

Do analysts recommend CBUS or QNCX?

Do institutionals & insiders have more ownership in CBUS or QNCX?

Which has preferable earnings and valuation, CBUS or QNCX?

Is CBUS or QNCX more profitable?

Does the media favor CBUS or QNCX?

Which has more volatility & risk, CBUS or QNCX?

Summary

How does Quince Therapeutics compare to Promis Neurosciences?

Which has stronger earnings and valuation, QNCX or PMN?

Which has more risk & volatility, QNCX or PMN?

Do analysts recommend QNCX or PMN?

Do insiders and institutionals believe in QNCX or PMN?

Does the media refer more to QNCX or PMN?

Is QNCX or PMN more profitable?

Summary

How does Quince Therapeutics compare to ADC Therapeutics?

Which has higher valuation & earnings, QNCX or ADCT?

Does the media prefer QNCX or ADCT?

Is QNCX or ADCT more profitable?

Do analysts prefer QNCX or ADCT?

Do institutionals and insiders hold more shares of QNCX or ADCT?

Which has more risk and volatility, QNCX or ADCT?

Summary

How does Quince Therapeutics compare to Genelux?

Do institutionals & insiders believe in QNCX or GNLX?

Is QNCX or GNLX more profitable?

Which has more risk and volatility, QNCX or GNLX?

Do analysts rate QNCX or GNLX?

Which has preferable valuation and earnings, QNCX or GNLX?

Does the media refer more to QNCX or GNLX?

Summary

How does Quince Therapeutics compare to Anixa Biosciences?

Do institutionals & insiders have more ownership in QNCX or ANIX?

Which has higher valuation & earnings, QNCX or ANIX?

Do analysts recommend QNCX or ANIX?

Is QNCX or ANIX more profitable?

Which has more risk & volatility, QNCX or ANIX?

Does the media refer more to QNCX or ANIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools